Amneal Pharma hit on Q2 miss and guidance cut

Amneal Pharmaceuticals (AMRX) Q2 results: Revenues: $404.6M (-2.2%).

Net Loss: ($16.9M) (+11.5%); Loss Per Share: ($0.13) (+13.3%); Non-GAAP Net Income: $26.7M (-61.8%); Non-GAAP EPS: $0.09 (-60.9%); CF Ops: ($87.3M) (-21.9%).

2019 Guidance: Adjusted EBITDA: $425M – 475M from $600M – 650M; Non-GAAP EPS: $0.52 – 0.62 from $0.94 – 1.04.

Shares are down 5% premarket.

Previously: Amneal Pharmaceuticals EPS misses by $0.03, misses on revenue (Aug. 5)

https://seekingalpha.com/news/3486765-amneal-pharma-5-percent-premarket-q2-miss-guidance-cut